Table 2. Comparison of National Institute of Health Stroke Scale scores among the five groups pre- and post-therapy.
| Groups | n | Pretherapy | Post-therapy | |||
|---|---|---|---|---|---|---|
| Day 11 | 90 days | |||||
| Abbreviations: ANOVA, analysis of variance; SD, standard deviation. Note: Values are expressed as mean ± SD. | ||||||
| 1 p < 0.001 versus the placebo group by ANOVA. | ||||||
| 2 p < 0.001 versus the placebo group by ANOVA. | ||||||
| 3 p = 0.90 versus the placebo group by ANOVA. | ||||||
| 4 p = 0.01 versus the placebo group by ANOVA. | ||||||
| a p < 0.001 versus the placebo group by ANOVA. | ||||||
| b p < 0.001 versus the placebo group by ANOVA. | ||||||
| c p = 0.29 versus the placebo group by ANOVA. | ||||||
| d p = 0.05 versus the placebo group by ANOVA. | ||||||
| * p -value significant. | ||||||
| Citicoline | 20 | 14.00 ± 4.34 | 8.90 ± 4.21 1,* | 3.53 ± 2.22 a , * | ||
| Edaravone | 20 | 13.25 ± 5.33 | 6.84 ± 3.60 2 , * | 2.94 ± 1.95 b , * | ||
| Minocycline | 20 | 13.10 ± 4.59 | 9.90 ± 4.90 3 | 4.82 ± 2.41 c | ||
| Cerebrolysin | 20 | 14.15 ± 5.30 | 9.05 ± 4.90 4 , * | 4.50 ± 3.23 d , * | ||
| Placebo | 20 | 13.35 ± 4.53 | 10.20 ± 4.70 | 5.82 ± 2.90 | ||